Source: http://ipkitten.blogspot.com/2018/12/breaking-tba-decides-that-rule-282-epc.html?showComment=1544125867867
Timestamp: 2019-05-23 22:50:47
Document Index: 586219359

Matched Legal Cases: ['Art. 53', 'Art. 164', 'CJEU ', 'CJEU ', 'CJEU ', 'CJEU ', 'Art 100', 'Art 138']

BREAKING: TBA decides that Rule 28(2) EPC, excluding plant products produced by essentially biological processes from patentability, is void - The IPKat
Home / Article 53(b) / essentially biological processes / plant patents / rule 28(2) / Syngenta / T 1063/18 / tba / BREAKING: TBA decides that Rule 28(2) EPC, excluding plant products produced by essentially biological processes from patentability, is void
Rose Hughes Thursday, December 06, 2018 - Article 53(b), essentially biological processes, plant patents, rule 28(2), Syngenta, T 1063/18, tba
IPKat has received breaking news that the Technical Board of Appeal (TBA) yesterday decided that recently amended Rule 28(2) EPC is in conflict with Art. 53(b) EPC as interpreted by the Enlarged Board of Appeal in G 2/12 (Broccoli/Tomato II). Further, according to the Art. 164(2) EPC the Articles prevail, thus rending the R. 28 amendment void.
The case is yet another development in the on-going legal confusion on the issue of whether plant products produced by essential biological processes are patentable. Article 53(c) EPC excludes from patentablity processes for producing plants and animals by essentially natural processes. Rule 28(2) was recently added to extend this exclusion to plant products produced by essentially biological processes. The TBA yesterday ruled that new Rule 28(2) is incompatible with Article 53(b) as previously interpreted by the Enlarged Board of Appeal, and therefore void.
The decision was issued in oral proceedings yesterday for T 1063/18, an appeal from the Examination Division against an objection under Rule 28(2). Rule 28(2) was amended in a 2017 decision of the Administrative Council (OJ EPO 2017, A56) to exclude plant products produced by essentially biological processes (e.g. natural breeding methods) from patentability. Rule 28(2) relates to Article 53(b), which excludes essentially biological processes for the production of plants or animals from patentability.
Protecting his tomatoes
Following a long-running legal saga, the Enlarged Board of Appeal (EBoA) decided in Broccoli/Tomatoes I (G 2/07 and G 1/08, IPKat post here), that Article 53(b) EPC excludes from patentability claims directed to an essentially biological process for the production of plants. The follow-up EBoA decisions Broccoli/Tomatoes II (G2/12 and G2/13, IPKat post here) found that the Article 53(b) exclusion should be interpreted narrowly. Particularly, Article 53(b) should not prevent claims directed to plants or plant products produced by essentially biological processes.
In wake of the Broccoli/Tomatoes II, the European Commission (EC) was asked by the European Parliament to review the Biotech Directive (Directive 98/44/EC). Article 4 of the Biotech Directive mirrors the wording of Article 53(b) EPC, and excludes from patentability essentially biological processes for producing plants and animals, but does not explicitly exclude products produced by such processes. The EC concluded that the intention of the Biotech Directive was to exclude products produced by essentially biological processes from patentability, not just the processes themselves. The EC position was thus at odds with the view of the Enlarged Boards of Appeal in Broccoli/Tomatoes II, but in line with the patent laws in some member states, including France, Germany, Italy and the Netherlands.
The Administrative Council of the EPO subsequently decided to amend the EPC regulations to reflect the EC's position (IPKat post here). Particularly, Rule 28 of the Implementing Regulations was amended to include the following paragraph:
The Administrative Council decision was considered a blow for the EU agritech industry, already hampered by arguably the world's most stringent GMO regulations, in the form of the GMO directive (recently ruled by the CJEU also to include gene-edited products, IPKat post here).
The appeal case decided yesterday, T 1063/18, related to Syngenta's EP patent application EP2753168. The application seeks protection for a pepper plant. The application was rejected by the Examining Division in view of the Rule 28 amendment. Syngenta filed a notice of appeal and statement of grounds in April 2018. The TBA agreed to expedite proceedings in view of the many pending applications to which the issue of new Rule 28 is relevant. Oral Proceedings were held yesterday, 5 December 2018. In view of the nature of the appeal, the EPO also decided to enlarge the number of members on the Board to include 3 technical members and 2 legal members. Third party observations were filed by the European See Agency (ESA), urging the board to maintain the rejection in view of Rule 28. Third party observations were also filed in support of Syngenta, for example by Solynta (a potato seed breeding company).
The EPO has not yet issued a statement regarding the decision, and IPKat is therefore indebted to our source and Katfriend Bart van Wezenbeek for information on the outcome of proceedings yesterday at the Board of Appeal, Haar. According to Bart, the Board found the matter so crystal clear that they did not see the need to refer the question to the Enlarged Board. Particularly, the Board found that Article164(2) EPC stipulates that the Articles have precedence over the rules, and the amendment to Rule 28 is therefore void. The Broccoli/Tomatoes II decisions therefore stand. The case has now be remitted back to the Examining Division, for examination on clarity and inventive step.
Yesterday's decision is an exciting turn of events for the European agritech industry. It seems that the legal uncertainty regarding plant and plant product inventions will continue for some time to come.
IPKat will, of course, bring you detailed analysis of the published decision once this has been issued.
BREAKING: TBA decides that Rule 28(2) EPC, excluding plant products produced by essentially biological processes from patentability, is void Reviewed by Rose Hughes on Thursday, December 06, 2018 Rating: 5
Anonymous Thursday, 6 December 2018 at 19:51:00 GMT
One correction, Solynta filed observations in support of Syngenta's position that the rule was incorrect, as did multiple other parties.
2010-2018 is not over! Friday, 7 December 2018 at 07:21:00 GMT
It was difficult to understand at the time why the then President of the EPO rushed to abide by comments of the Commission and proposed to introduce in the Implementing regulations further amendments to R 27 and 28. If it had been a decision on the CJEU, why not, but even then, there are 38 member states at the EPO and only 28/27 in the European Union. It was a mere position paper of the commission.
One can even be inclined to think, that in its rage against the Boards of Appeal, the then President took every pretext to bash on them. Personal revenge should however not be the motor for changing the rules of a game.
The ball is indeed now again in the court of the AC and it is good so. When the AC decided the amendment, it was the wilful instrument of the then President of the EPO, and, as was said many times, it was the tail wagging the dog. The same can be said about the relocation of the Boards to a suburb of Munich in order "to increase the perception of their independence". That this relocation would not improve the situation of the Boards, should have been more than obvious to anybody thinking straight. But the AC agreed!
I am not sure that the situation will change. It just shows what damage can be made to a system by the wish of destruction and revenge of a single individual supported by a group of people playing the farcical "Yes, Prime Minister".
By the way, it is not the first time that the Boards do not agree on a decision taken by the AC. See G 6/95. On the other hand, when one sees the actual draft RPBA, according to which it will be mandatory for a Board to send an annex with the summons, one can only smile at what happened then.
Rose Hughes Friday, 7 December 2018 at 09:35:00 GMT
Thank you for pointing this out. We have corrected the post.
Canter Friday, 7 December 2018 at 21:14:00 GMT
Well it's an exciting turn of events for patent attorneys also as it's not every day that an EPC rule is declared void.
National courts and the CJEU are bound by the Biotech Directive and so presumably are duty bound to follow the EU's interpretation of this, which is that the products of essentially biological processes are not patentable, and so I suspect claims to them will be declared invalid in any litigation.
Cees Mulder Saturday, 8 December 2018 at 15:55:00 GMT
On 7 December 2018, the EPO posted a report on its website relating to the decision:
https://www.epo.org/law-practice/case-law-appeals/communications/2018/20181207.html
EPO is not EU and will probably never be Saturday, 8 December 2018 at 20:57:00 GMT
Dear Mr Canter,
You seem to forget that the EPC has 38 member states and the EU presently 28 and soon only 27. You might thus have a long time to wait until the EU takes control of the EPO on the pretext of harmony.
If the EU could have taken over the EPO, we would not have to do with the UPC, but EPLA would probably be in place now. However, Opinion C 1/09 came in between.
I do not think that even the children of my grandchildren will see the EU take the control of the EPO!
Canter Sunday, 9 December 2018 at 19:34:00 GMT
In response to 'EPO is not EU...', please see http://patentblog.kluweriplaw.com/2018/05/08/eu-bring-unitary-patent-system-control/
Already the economic and academic arguments are being made as can be seen in that article. The EPO is being entrusted with the Unitary Patent, but that will bring the responsibility of harmonising with EU. It does not make sense to have 2 different sets of appeal systems in Europe (The EPO Boards and the CJEU). A single system of control is sensible, and I am sure will come into being at some point.
Proof of the pudding Monday, 10 December 2018 at 15:53:00 GMT
I would like to address a number of inaccuracies in (implied) statements in your comment from 7 December.
Firstly, it is the Member States that are bound by the Biotech Directive. The role of the courts is to interpret that legislation, ie to determine the meaning of rules that bind the Member States (and other individuals / entities towards which those rules are directed).
Secondly, only the CJEU is able to provide a binding interpretation of the Biotech Directive. Whilst the views of the Commission and of the Member States may be of interest, they are meaningless if they do not align with the CJEU's interpretation of that Directive.
Thirdly, there has already been national litigation (in the Netherlands) on relevant claims. Contrary to what you asserted would be the inevitable result, those claims were held by the Dutch court not to be excluded from patentability.
Finally, as has already been pointed out, Opinion 1/09 closes the door to the EPO becoming an EU institution. Indeed, it is not 100% clear whether the EPO as it currently stands is compliant with EU law. In this respect, a positive aspect of the Board of Appeal's decision is that it avoided an outcome that would have been a blatant example of non-compliance with EU law (specifically, with Article 267 TFEU, which is essential to preserving the autonomy and supremacy of EU law).
Canter Tuesday, 11 December 2018 at 09:55:00 GMT
Proof of the Pudding, I completely agree with everything you have written, but I would also point out the broader set of events that happened. The Enlarged Board ruled that products of essentially biological processes were patentable. The EU Commission disagreed. The EPC rules were changed to comply with the Commission's view. This is power politics at play, and a reflection of the hard reality. The EU is an ongoing project which is ever-expanding and patents are something it has an interest in. The EU will ultimately not allow the EPO to dissent in any substantial way. Whilst 'legally' speaking you are correct, I fear that ultimately the EPO will end up being an EU institution at some point because it does not have the power to resist. The EU has recently proposed changes to SPC rights (http://europa.eu/rapid/press-release_IP-18-3907_en.htm). At some point or other it is bound to review patent protection and perhaps how validity is determined, and that will inevitably require the EPO to comply with whatever the EU wants.
Proof of the pudding Tuesday, 11 December 2018 at 12:28:00 GMT
If by "power politics" you mean a breach of democratic norms (including the separation of powers between the executive, legislative and judicial branches), then I agree that this is what is currently in play.
From this perspective, I continue to believe that it is extremely unlikely that the EPO will be converted into an EU institution, as the circumstances are unlikely to arise where the pain caused by such a change (which would almost certainly include restricting membership of the EPO to EU states only) wold be seen as "worth it" by all stakeholders.
The comparison to SPCs is inappropriate. EU-wide SPC protection was created for the first time under EU law. The same is not true for (more or less "harmonised") EU-wide patent protection. We have a well-established (and largely well-functioning) system that exists under international law. The consequences of the EU creating an entire patent system under EU law would therefore be far more profound and unsettling (as well as potentially unpleasant).
'EPO is not EU...' Friday, 14 December 2018 at 07:27:00 GMT
You consider that “The EPO is being entrusted with the Unitary Patent”. This is not completely correct. It is entrusted with keeping a register of UP and to collect the annual fees for UP. It is difficult to see in those two points the full responsibility of the EPO for UP.
On the other hand, you put the finger on one of the big drawbacks when it comes to the UPC.
What if, in matter of validity, the case law of the UPC will differ with the case law of the BA and more with that of the EBA. This is a fundamental uncertainty, and I would say flaw of the UPC system. At least between the EFTA court and the CJEU there has been an agreement to exchange information. Between the UPC and the EBA/BA nope. This must have a reason. May be the aim behind this is the end of the EBA/BA?
On the other hand, why should 10 states, some of them having also a strong economic holding, but outside the EU, accept judgements of a court only acting within the EU?
There would have been one solution that is for the UPC only to deal with infringement, and let the EBA/BA decide on validity. A kind of general bifurcation to use a naughty word.
This would mean that the opposition period would have to be extended to the life time of the patent, and not merely limited to 9 months. After all, a proprietor may amend its EP during its whole life, thus why limit the possibility to challenge the patent centrally only for 9 months after grant?
This could have been good for unification of law within Europe, and would have avoided any clash of case law. This solution would certainly not be to the liking of all the lobbies who absolutely wanted the UPC, for whatever reason.
In this system, validity could be assessed in a consistent way by a court systematically composed of technical judges, and not just by technical judges which are all in a pool, and can be called or not at the discretion of the judges sitting in the local or regional courts of first instance of the UPC.
When it comes to infringement, then the UPC could act, but only on this point.
By deciding both on infringement and validity, clashes are necessarily programmed. Just look at the way added subject-matter is dealt with at the EPO. It is not a secret that the way added matter is looked at by the BA/EBA, is very strict, and for good reasons, but to the dislike of plenty of users. By doing so, they actually forget that the added-matter and novelty are the two sides of the same coin: what you lose on on side you gain on the other.
Let’s take the example of the German Federal Court (BGH): if an independent claim comprises a feature extending over the original disclosure, the unallowable feature is merely to be disregarded when assessing patentability, cf. X ZR 161/12 (Wundbehandlungsvorrichtung=Wound treatment device). This means that the application is refused and the patent revoked.
Before the EPO G 1/93 (the inescapable trap) is valid. When it comes to added subject-matter during examination, then the position of the BGH is the same as the BA/EBA. See BGH X ZB 5/16 (Phosphatidylcholine).
Imagine we end up with a similar situation when it comes to the UPC. Is such a difference in legal approach, on actually the same legal text (Art 100-Art 138 EPC) in the interest of European Industry, and especially SMEs? I have some doubts.
The whole UPC system has been rushed into place following an intense lobbying whereby the apparent interests for SMEs has been used as a fig leaf. Politicians have not been aware of what was coming on. A last point: filings at the EPO stemming from EU member states count for at most for a third. That means that two thirds come from outside the EU. As the number of grants more or less follow the same distribution, I have not yet met anybody capable of explaining, how this can be profitable for European Industry and especially the SMEs.